Abstract

Purpose To quantify the long-term evaluation of optic chiasma (OC) and/or optic nerve(s) (ONs) and to develop predictive models for radiation-induced optic neuropathy (RION) in nasopharyngeal carcinoma after intensity-modulated radiotherapy (IMRT). Methods and Materials A total of 3,662 patients' OC/ONs with full visual acuity and dosimetry data between 2010 and 2015 were identified. Critical dosimetry predictors of RION were chosen by machine learning and penalized regression for survival. A nomogram containing dosimetry and clinical variables was generated for predicting RION-free survival. Results The median follow-up was 71.79 (2.63–120.9) months. Sixty-six eyes in 51 patients (1.39%) developed RION. Two patients were visual field deficient, and 49 patients had visual acuity of less than 0.1 (20/200). The median latency time was 36 (3–90) months. The 3-, 5-, and 8-year cumulative incidence of RION was 0.78%, 1.19%, and 1.97%, respectively. Dmax was the most critical dosimetry variable for RION (AUC: 0.9434, the optimal cutoff: 64.48 Gy). Patients with a Dmax ≥64.48 Gy had a significantly higher risk of RION (HR = 102.25; 95%CI, 24.86–420.59; P < 0.001). Age (>44 years) (HR = 2.234, 95% CI = 1.233–4.051, p = 0.008), advanced T stage (T3 vs. T1-2: HR = 7.516, 95% CI = 1.725–32.767, p=0.007; T4 vs. T1-2: HR = 37.189, 95% CI = 8.796–157.266, P < 0.001), and tumor infiltration/compression of the OC/ONs (HR = 4.572, 95% CI = 1.316–15.874, p=0.017) were significant clinical risk factors of RION. A nomogram comprising age, T stage, tumor infiltration/compression of the OC/ON, and Dmax significantly outperformed the model, with only Dmax predicting RION (C-index: 0.916 vs. 0.880, P < 0.001 in the training set; 0.899 vs. 0.874, P=0.038 in the test set). The nomogram-defined high-risk group had a worse 8-year RION-free survival. Conclusions In the IMRT era, Dmax <60 Gy is safe and represents an acceptable dose constraint for most NPC patients receiving IMRT. A reasonable trade-off for selected patients with unsatisfactory tumor coverage due to proximity to the optic apparatus would be Dmax <65 Gy. Caution should be exercised when treating elderly and advanced T-stage patients or those with tumor infiltration/compression of the OC/ON. Our nomogram shows strong efficacy in predicting RION.

Highlights

  • Radiation-induced optic neuropathy (RION) is a rare and catastrophic late-onset complication after radiation therapy (RT) to the optic chiasma (OC) and/or optic nerve(s) (ONs) in head and neck cancer (HNC)

  • Visual acuity postIMRT had only mildly decreased [5]. erefore, it appears that the incidence of RION remains low even if patients exceed the recommended dose constraint. us, the question of whether the recommended dose constraint for the OC/ONs is relatively conservative in the modern intensity-modulated radiotherapy (IMRT) era possibly diminishes the probability of a cancer cure

  • A flowchart of the patient inclusion criteria is shown in Supplementary Figure 1. e authenticity of this study has been validated by uploading the key raw data onto the Research Data Deposit public platform (RDDA2022229679). is project was approved by Sun Yat-sen University Cancer Center (SYSUCC)’s institutional review committee (B2020-142-01)

Read more

Summary

Introduction

Radiation-induced optic neuropathy (RION) is a rare and catastrophic late-onset complication after radiation therapy (RT) to the optic chiasma (OC) and/or optic nerve(s) (ONs) in head and neck cancer (HNC). It usually presents as acute, painless, progressive, and irreversible loss of vision or hemianopsia in one or both eyes in the months to years after treatment [1]. In a recent study of 125 patients with a Dmax to the anterior visual pathway of ≥50 Gy undergoing IMRT, five patients were diagnosed with RION. Erefore, it appears that the incidence of RION remains low even if patients exceed the recommended dose constraint. Visual acuity postIMRT had only mildly decreased [5]. erefore, it appears that the incidence of RION remains low even if patients exceed the recommended dose constraint. us, the question of whether the recommended dose constraint for the OC/ONs is relatively conservative in the modern IMRT era possibly diminishes the probability of a cancer cure

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call